279 results about "Viral infectious disease" patented technology

The invention relates to chimeric antigen receptors (CAR), particularly relates to dual-signal independent chimeric antigen receptors (dsCAR), and also relates to immune response cells of the dual-signal independent chimeric antigen receptors (dsCAR) and uses of the immune response cells in preparation of drugs for treatment of malignant tumor and virus infected diseases. In detail, the dual-signal independent chimeric antigen receptors (dsCAR) can respectively identify two different family antigens of tumor cells and can respectively transmit two T-cell-activation related signals. One of the CAR can transmit a first T-cell-activation related signal by combing a ligand of a tumor specific antigen or a tumor-associated antigen to decide T-cell killing specificity, and the other CAR can transmit a second T-cell-activation related signal by combing a ligand of a membrane receptor (such as EGFR (epidermal growth factor receptor) family protein) widely expressed by the tumor cells to promote T cell activation, proliferation and survival. The dual-signal independent chimeric antigen receptors (dsCAR) can avoid the potential safety problems on the basis of maintaining curative effects of second generation and third generation CAR.

This invention relates to a cysteine protease inhibitor comprising casein which is a protein derived from milk, a partial peptide of casein, and/or hydrolysate of casein as an active ingredient. The cysteine protease inhibitor of the present invention can be used as preventive or therapeutic drug for osteoporosis, malignant hypercalcemia, breast cancer, prostate cancer, periodontitis or bacterial and viral infectious diseases, and food, drink, feed and the like.

A novel nitrogen-containing compound effective against diseases such as HIV viral infectious diseases, rheumatism, and cancerous metastasis. It is a nitrogen-containing compound represented by the following general formula (1). In the formula, A typically represents a group represented by the formula (2) (A1 is hydrogen or an optionally substituted, mono- or polycyclic, heteroaromatic or aromatic ring; G1 is a single bond or a hydrocarbon group represented by the following formula (3) wherein R1, R2, and R3 may be optionally substituted hydrocarbon groups); W is an optionally substituted hydrocarbon group or heterocyclic ring; x is -C(=O)NH-; y is -C(=O)-; and D1 is hydrogen atom, alkyl having a polycyclic aromatic ring, di(substituted alkyl)amine, or alicyclic amine.

The invention belongs to the fields of immunology and cytobiology and relates to a molecular brake for rapidly stopping the killing effect of CAR-T (T cell engineered with chimeric antigen receptors) and an application of the molecular brake. Specifically, the molecular brake serving as an element is inserted into the specific position in the CAR and can rapidly stop the killing effect of the CAR-T on a target cell, thereby effectively improving the safety of CAR-T treatment. The invention further relates to immunoreactive cells expressing the CAR and an application of the immunoreactive cells in preparation of drugs for treating malignant tumors or virus infectious diseases.

The invention provides medicated soap for aiding in preventing and treating acne, eliminating cosmetic allergy and thoroughly removing remaining cosmetic from face, which has the effects on resisting bacteria, diminishing inflammation, promoting blood circulation of skin, preventing skin allergy and the like. The medicated soap has a faint scent and abundant foam, is convenient in use without side effect, can be used for cleaning skin and washing hands normally, and can prevent many kinds of bacterial and viral infectious diseases.

The invention relates to an isoquinoline compound shown as a formula (A) or a stereoisomer, a pharmaceutically acceptable salt, a hydrate, a solvate or a crystal thereof, a medicinal composition thereof and application thereof as antiviral medicines. The isoquinoline compound inhibits hepatitis B DNA activity and hepatitis B surface antigen activity at the same time. The invention particularly relates to application thereof to preparation of medicines for treating and/or preventing hepatitis B, hepatitis B viruses (HBV) thereof and other viral infectious diseases, in particular to treatment and/or prevention of the hepatitis B and the hepatitis B viruses as HBV Surface antigen inhibitor medicines and HBV DNA production inhibitor medicines.

The invention belongs to the field of antivirus in medical chemistry, and relates to preparation of non-cyclic nucleotide phosphoamides and salts thereof and application of the non-cyclic nucleotide phosphoamides and salts thereof in treating human immunodeficiency virus (HIV), hepatitis B, hepatitis B virus (HBV) and other virus infection diseases. The non-cyclic nucleotide phosphoamides, and isomers, pharmaceutically acceptable salts, hydrates, solvates or crystals thereof have the general formula I of which the structure is disclosed in the specification. The invention also provides a pharmaceutical composition containing the compounds and isomers, pharmaceutically acceptable salts, hydrates, solvates or crystals thereof, and application of the compounds or composition in treating and/or preventing HIV and HBV infection. The compounds provided by the invention have the advantages of favorable anti-HIV and HBV activities, low oral dosage and low toxicity.

The invention provides an application of protocatechuic acid in the preparation of drugs for preventing and controlling livestock and poultry virus infectious diseases. The viruses include infectious bursal disease virus, avian influenza virus, infectious bronchitis virus and/or porcine transmissible gastroenteri tis virus. Meanwhile, the invention also relates to a protocatechuic acid preparation and a preparation method thereof.

The invention provides a paeonia plant extract and a preparation method and applications thereof. The extract is prepared from paeonia seed cases, wherein the content of total polyphenol is 40%-90%, and the total polyphenol contains stilbene ingredient. Proved by experiment research, the extract or drug composition thereof can be used for preventing or treating fungus infection diseases, virus infection disease, cancer and other diseases.

The invention belongs to the field of medicines and particularly relates to a new application of an iridoid glycoside compound, genipin-1-[beta]-D-gentiobioside, and a composition composed by compounding the genipin-1-[beta]-Dgentiobioside with other components as effective components for preparing antiviral drugs, antibacterial drugs, fever alleviating drugs, inflammation resistant drugs and anti-oxidizing drugs. The iridoid glycoside compound and the composition can be used for treating acute respiratory infection, flu, pneumonia, viral hepatitis type B, herpes zoster, herpes viral keratitis, viral myocarditis, Epstein-Barr virus infection, retrovirus infectious diseases and bacterial infectious diseases.

The object of the present invention is to provide a compound useful for the prevention and treatment of viral infectious diseases, and particularly liver diseases caused by HCV infection due to its having a high degree of replication inhibitory activity against HCV, its production method, an intermediate compound useful for its production and a pharmaceutical composition containing these compounds, and the present invention relates to a compound represented by the formula (I):

(wherein A represents —(CH₂)_n—, etc.; B represents —(C═O)—, etc.; D represents —(CH₂)_m—R′, etc.; E represents a hydrogen atom, etc.; G represents —(CH₂)_p-J, etc.; bond Q represents a single bond or double bond; and R₁, R₂ and R₃ may be the same or different and each represent a hydrogen atom, etc.), a prodrug thereof or a pharmaceutically acceptable salt thereof.

The invention relates to a phosphonate prodrug of an adenine derivative and medical application of the phosphonate prodrug. Specifically, the invention relates to a compound shown in a general formula (I) or an optical isomer, or a pharmaceutical salt, or a hydrate or a solvate of the compound, and application of the compound or the optical isomer, or the pharmaceutical salt, or the hydrate or the solvate of the compound to preparation of medicines for curing virus infective diseases, especially hepatitis B (HBV) and acquired immune deficiency syndrome (HIV), wherein the definitions of all substituents in the general formula (I) are the same as the definitions in the specification.

The invention discloses a traditional Chinese medicine combination for healthcare and treatment of livestock. The traditional Chinese medicine combination is prepared by following traditional Chinese medicines: by weight, 40-50 parts of root of hairy asiabell, 40-50 parts of white atractylodes rhizome, 40-50 parts of tuckahoe, 30-40 parts of Chinese angelica, 30-40 parts of rhizoma ligustici wallichii, 30-40 parts of scutellaria baicalensis, 30-40 parts of radix rehmanniae, 40-50 parts of folium isatidis, 30-40 parts of cortex moutan radicis, 30-40 parts of tenuifolia, 30-40 parts of divaricate saposhnikovia roots and 30-40 parts of licorice roots. Firstly, the traditional Chinese medicines in the prescription of the traditional Chinese medicine combination are natural medicines, and cannot cause drug residue or cause micro drug residue when widely applied to livestock products, secondly, drug resistance and drug tolerance of original microorganisms of the livestock cannot be caused, the traditional Chinese medicine combination is favorable for treating diseases of the livestock, and thirdly, the traditional Chinese medicine combination has disease prevention and healthcare function, increases resistance of bodies of the livestock while realizing bacteriostasis and inframicrobe resistance, improves immunity of the bodies of the livestock, is favorable for the livestock to be recovered from viral infectious diseases, and remarkably increases production benefit and economic benefit of the animal husbandry.

The invention discloses compounds having virus resistance and a composition thereof. The composition comprises one or more of the 13 compounds comprising 6'-O-caffeoyl deacetyl asperulosidic acid methyl ester. The compounds having virus resistance and the composition thereof can be extracted from plants and can also be prepared by synthesis. The composition comprising the compounds having virus resistance can prevent and treat viral infection-caused diseases such as influenza, myocarditis, conjunctivitis, viral pneumonia, encephalitis, leukemia, hepatitis B, hepatitis C, AIDS, genitourinary system infection, EB virus infection, human papillomavirus infection and cytomegalovirus infection. The composition can be prepared into an oral preparation, an injection, a spray, a subcutaneous injection and an anus suppository.

The object of the present invention is to provide a pharmaceutical composition for preventing or treating viral infectious diseases. The compounds of the present invention have extremely potent anti-HCV activity and HCV growth inhibitory effects, and since they also only demonstrate mild cytotoxicity in vivo, a pharmaceutical composition containing the compound of the present invention is extremely useful as an anti-HCV preventive/therapeutic agent.

The invention relates to application of an AlkB homologous 5 (ALKBH5) inhibitor of demethylase in the treatment of virus infectious diseases. In particular, the invention relates to the use of the ALKBH5 inhibitor in the preparation of products for the treatment of the virus infectious diseases and/or diseases and/or symptoms related to virus infection, and a corresponding pharmaceutical composition or kit of the products. The application can be used for inhibiting and treating the virus infection, especially for objects with abnormal natural immune functions, and has a wide application prospect.

The present invention relates to purposes of giant knotweed extract. The in vitro anti-HIV experiment shows that resveratrol 3-O-Beta-D- glucoside 2íÕ-sulfate sodium or potash salt and resveratrol 3-O-Beta-D- glucoside 4íÕ-sulfate sodium or potash salt show significant activity of resisting hepatitis B virus; resveratrol 3-O-Beta-D- glucoside 2íÕ-sulfate sodium or potash salt also has significant HIV inhibited effect. The virus infectious diseases such as AIDS and hepatitis B poses a serious threat to human's health and life and hepatitis B is one of the major diseases affecting human's health. The present invention provides a lead compound for doing R&D of novel anti-HIV and hepatitis B virus medicines and also a novel medicine source for clinic application, thus having a significant value to develop and utilize the medical plant resources of our country.

The invention relates to a tenofovir prodrug and pharmaceutical uses thereof. In particular, the invention relates to a compound as shown in general formula (I):

and its isomer, pharmaceutically acceptable salt, hydrate or solvate, as well as their uses in preparing drugs for treating viral infectious diseases, especially HIV infection, hepatitis B, or diseases caused by hepatitis B virus, wherein the definition of each substituent in the general formula (I) is as defined in the specification.

The invention relates to the field of biological pharmacy, in particular to a recombinant long-acting interferon fusion protein and application thereof. The technical problem to be solved is to improve internal action time of the interferon and provide a fusion protein. The fusion protein consists of an N-end interferon, C-terminal human albumin binding peptide and glycin linking peptide which links between the N-end interferon and the C-terminal human albumin binding peptide. The protein can be expressed efficiently in colon bacillus, is simple in purification process and can be used for large-scale industrial production and preparation of a pharmaceutical grade rcIFN-ABP fusion protein pure product. Compared with the recombinant cognate interferon (rcIFN) per se, the rcIFN-ABP fusion protein obtained by using the invention has the characteristic of longer blood serum half-life period. Meanwhile, the specificity antivirus ratio activity is equivalent to cIFN. The rcIFN-ABP fusion protein can be used for treating virus infectious diseases, such as AIDS, hepatitis, SARS, bird flu and the like, and also can be used for treating tumors and other cell proliferative diseases.

The invention discloses a traditional Chinese medicine composition for treating viral respiratory tract infection and a preparation method thereof. The composition comprises the following raw medicinal materials in parts by weight: 3-20 parts of honey-fried ephedra, 3-20 parts of flos farfarae, 5-25 parts of schizonepeta spike, 5-20 parts of radix asteris, 5-15 parts of apricot kernel, 5-20 parts of roasted perilla seed, 3-15 parts of rhizoma anemarrhenae, 3-15 parts of bulbus fritillariae thunbergii, 5-25 parts of fructus arctii, and 2-15 parts of liquorice. The raw medicinal materials are matched with auxiliary materials and a flavoring agent to be directly or indirectly made into pharmaceutically acceptable capsules, oral liquid, granules, syrup, tablets, effervescent particles, dropping pills, aerosol, spraying agent, gargle, mouthwash and a variety of dosage forms via conventional processes. The traditional Chinese medicine composition can be clinically used for treating or preventing the respiratory tract viral infectious diseases caused by influenza A virus, influenza B virus, rhino virus, coronavirus, respiratory syncytial virus, hand, foot and mouth virus, adenovirus, parainfluenza virus, echovirus, coxsackievirus and the like.

The invention relates to a Chinese traditional medicine veterinary medicine used for the treatment of bacterial and viral infectious diseases for livestock and poultry, and the preparation method thereof. The invention is characterized in that the veterinary medicine is composed of the following components by weight portion: 5-25 portions of rhizoma coptidis, 3-18 portions of dock root radix rumicis and 20-60 portions of carrier. The Chinese traditional medicine veterinary medicine used for the treatment of bacterial and viral infectious diseases for livestock and poultry is prepared through the functional ingredients processed in the steps of crushing, decoction, condensation, drying, spraying and forming powder; then, the powder is mixed with the carrier to prepare pure Chinese traditional combination which maintains the active ingredients and of the components and has the advantages of good solubility, quick absorption, obvious curative effects, having no toxic and side effects, avoiding the veterinary residue and social hazard.

The invention discloses a traditional Chinese medicine composition for treating respiratory tract viral infectious diseases and a preparation method thereof. The composition comprises the following active pharmaceutical ingredients in parts by weight: 5-25g of perilla leaf, 5-25g of tatarian aster root, 5-25g of Chinese thorowax root, 5-25g of schizonepeta spike, 5-25g of great burdock achene, 5-25g of apricot seed and 1-15g of liquoric root. The active pharmaceutical ingredients can be matched with excipients and a flavoring agent to be directly or indirectly prepared into pharmaceutically acceptable capsules, oral liquid, granules, syrup, tablets, effervescent particles, dropping pills, aerosol, spraying agent, gargle, mouthwash and a variety of formulations via conventional process steps. The traditional Chinese medicine composition can be clinically used for treating or preventing the respiratory tract viral infectious diseases caused by influenza A virus, influenza B virus, rhino virus, coronavirus, respiratory syncytial virus, adenovirus, parainfluenza virus, enteric cytopathogenichuman orphan virus, Coxsackie virus and the like.

The invention discloses an antiviral protein RC28, the amino acid thereof is shown in SEQ ID NO.1, and the preparation method thereof comprises the following steps: crude separation is carried out to obtain crude extract of RC28, molecular sieve chromatography and ion exchange chromatography are used to further carry out separation and purification to obtain RC28 protein product. The antiviral protein RC28 of the invention has good antiviral activity, and provides an efficient and safe new way for treating virus infection, in particular to enveloped virus infection diseases.